In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``One Dollar Coin and Community 
Development Act of 1994''.

SEC. 2. ONE DOLLAR COINS.

    (a) Color and Content.--Section 5112(b) of title 31, United States 
Code, is amended--
            (1) in the 1st sentence, by striking ``dollar,''; and
            (2) by inserting after the 4th sentence, the following new 
        sentence: ``The dollar coin shall be golden in color, have an 
        unreeded edge, have tactile and visual features that make the 
        denomination of the coin readily discernible, be minted and 
        fabricated in the United States, and have such metallic, 
        anticounterfeiting properties as United States clad coinage in 
        circulation on the date of the enactment of the One Dollar Coin 
        and Community Development Act of 1994.''.
    (b) Design of Dollar Coin.--Section 5112(d)(1) of title 31, United 
States Code, is amended by striking the 5th and 6th sentences and 
inserting the following new sentence: ``The Secretary of the Treasury 
shall select an appropriate design for the obverse side of the 
dollar.''.
    (c) Effective Date.--Not later than 18 months after the date of 
enactment of this Act, the Secretary of the Treasury shall place into 
circulation 1 dollar coins authorized under subsection (a)(1) of 
section 5112 of title 31, United States Code, which comply with the 
design requirements of subsections (b) and (d)(1) of such section, as 
amended by subsections (a) and (b) of this section. The Secretary may 
include such coins in any numismatic set produced by the United States 
Mint before the date the coins are placed in circulation.

SEC. 3. CEASING ISSUANCE OF ONE DOLLAR NOTES.

    (a) In General.--After the date that coins described in section 
2(c) are first placed in circulation, no Federal reserve bank may order 
or place into circulation any $1 Federal reserve note.
    (b) Redemption of $1 Notes.--
            (1) In general.--Section 5119(b)(1) of title 31, United 
        States Code, is amended by adding at the end the following new 
        subparagraph:
                    ``(F) Federal reserve notes in the denomination of 
                $1.''.
            (2) Effective date.--
                    (A) In general.--The amendment made by paragraph 
                (1) shall take effect on the date on which coins minted 
                pursuant to the amendments made by section 2 are first 
                placed in circulation.
                    (B) Notice of effective date.--The Secretary of the 
                Treasury shall publish a notice in the Federal Register 
                of the date on which the amendment made by paragraph 
                (1) takes effect in accordance with subparagraph (A) of 
                this paragraph.
    (c) Exception.--The Secretary of the Treasury shall produce only 
such Federal reserve notes of 1 dollar denomination as are required 
from time to time to meet the needs of collectors of this series. Such 
notes shall be produced in sheets and sold by the Secretary, in whole, 
or in part, at a price that exceeds the face value of the currency by 
an amount that, at a minimum, reimburses the Secretary for the cost of 
production.

SEC. 4. RESERVE FUND FOR CIRCULATING COINAGE.

    (a) Establishment.--Section 5111(b) of title 31, United States 
Code, is amended to read as follows:
    ``(b) Coinage Funds.--
            ``(1) Coinage metal fund.--The Secretary of the Treasury--
                    ``(A) shall maintain a coinage metal fund in the 
                Department of the Treasury; and
                    ``(B) may use the fund to buy metal to mint coins.
            ``(2) Circulating coinage reserve fund.--
                    ``(A) Establishment.--The Secretary of the Treasury 
                shall maintain a circulating coinage reserve fund in 
                the Department of the Treasury.
                    ``(B) Credits and debits.--The Secretary shall--
                            ``(i) credit the coinage reserve fund with 
                        the amount by which the nominal value of the 
                        coins minted and placed into circulation under 
                        this subchapter (other than numismatic items) 
                        exceeds the cost of the metal; and
                            ``(ii) charge the account with--
                                    ``(I) the waste incurred in minting 
                                the coins referred to in clause (i); 
                                and
                                    ``(II) the cost of distributing the 
                                coins, including the cost of coin bags 
                                and pallets.
                    ``(C) Availability of funds for community 
                development.--
                            ``(i) In general.--Effective for any fiscal 
                        year only to the extent and in such amounts as 
                        are provided in advance in appropriation Acts, 
                        the Secretary may lend excess amounts in the 
                        circulating coinage reserve fund to the 
                        Community Development Institutions Fund for the 
                        provision of financial assistance by such Fund 
                        through deposits, credit union shares, and 
                        loans in accordance with section 108 of the 
                        Community Development Banking and Financial 
                        Institutions Act of 1994.
                            ``(ii) Terms and conditions.--Any loan by 
                        the Secretary to the Community Development 
                        Institutions Fund in accordance with clause (i) 
                        shall bear such rate of interest and be subject 
                        to such other terms and conditions as the 
                        Secretary determines to be appropriate.
                    ``(D) Investment of balance in account.--Subject to 
                subparagraph (C), the Secretary of the Treasury shall 
                invest excess amounts in the circulating coinage 
                reserve fund in--
                            ``(i) instruments issued by the Secretary 
                        under chapter 31; and
                            ``(ii) other instruments to the extent, and 
                        in such amounts, as may be authorized by law.
                    ``(E) Payment to general fund.--Interest, 
                dividends, and other earnings on investments of the 
                circulating coinage reserve fund, including interest on 
                loans to the Community Development Financial 
                Institutions Fund, shall be paid into the general fund 
                of the Treasury to assist in reducing the deficit.''.
    (b) Termination of Coinage Profit Fund.--The coinage profit fund is 
hereby abolished and any balance in the account as of such termination 
shall be transferred by the Secretary to the circulating coinage 
reserve fund established pursuant to the amendment made by subsection 
(a) as soon as practicable after the date of the enactment of this Act.

Output: One Dollar Coin and Community Development Act of 1994 - Amends Federal monetary law to prescribe specifications for and design of dollar coins, including a golden color. 
Proscribes any issuance of one dollar notes after the date that dollar coins are first placed in circulation.  Prescribes guidelines for the redemption of one dollar notes. 
Directs the Secretary of the Treasury to establish:  (1) a coinage metal fund; and (2) a circulating coinage reserve fund. 
Authorizes the Secretary to lend excess amounts in the circulating coinage reserve fund to the Community Development Institutions Fund to enable it to provide financial assistance.  Mandates that earnings on investments of the circulating coinage reserve fund be paid into the general fund of the Treasury. 
Abolishes the coinage profit fund.  Transfers the balance of its account to the circulating coinage reserve fund.


Input: Consider Input: SECTION 1. ESTABLISHMENT OF NEW FASHION MODEL NONIMMIGRANT 
              CLASSIFICATION.

    (a) In General.--
            (1) New classification.--Section 101(a)(15)(P) of the 
        Immigration and Nationality Act (8 U.S.C. 1101(a)(15)(P)) is 
        amended--
                    (A) in clause (iii), by striking ``or'' at the end;
                    (B) in clause (iv), by striking ``clause (i), (ii), 
                or (iii)'' and inserting ``clause (i), (ii), (iii), or 
                (iv)'';
                    (C) by redesignating clause (iv) as clause (v); and
                    (D) by inserting after clause (iii) the following:
                    ``(iv) is a fashion model who is of distinguished 
                merit and ability and who is seeking to enter the 
                United States temporarily to perform fashion modeling 
                services that involve events or productions which have 
                a distinguished reputation or that are performed for an 
                organization or establishment that has a distinguished 
                reputation for, or a record of, utilizing prominent 
                modeling talent; or''.
            (2) Authorized period of stay.--Section 214(a)(2)(B) of the 
        Immigration and Nationality Act (8 U.S.C. 1184(a)(2)(B)) is 
        amended in the second sentence--
                    (A) by inserting ``or fashion models'' after 
                ``athletes''; and
                    (B) by inserting ``or fashion model'' after 
                ``athlete''.
            (3) Numerical limitation.--Section 214(c)(4) of the 
        Immigration and Nationality Act (8 U.S.C. 1184(c)(4)) is 
        amended by adding at the end the following:
    ``(I)(i) The total number of aliens who may be issued visas or 
otherwise provided nonimmigrant status during any fiscal year under 
section 101(a)(15)(P)(iv) may not exceed 1,000.
    ``(ii) The numerical limitation established by clause (i) shall 
only apply to principal aliens and not to the spouses or children of 
such aliens.
    ``(iii) An alien who has already been counted toward the limitation 
established by clause (i) shall not be counted again during the same 
period of stay or authorized extension under subsection (a)(2)(B), 
irrespective of whether there is a change in petitioner under 
subparagraph (C).''.
            (4) Consultation.--
                    (A) In general.--Section 214(c)(4)(D) of the 
                Immigration and Nationality Act (8 U.S.C. 
                1184(c)(4)(D)) is amended by striking ``clause (i) or 
                (iii)'' and inserting ``clause (i), (iii), or (iv)''.
                    (B) Advisory opinion.--Section 214(c)(6)(A)(iii) of 
                the Immigration and Nationality Act (8 U.S.C. 
                1184(c)(6)(A)(iii)) is amended--
                            (i) by striking ``section 101(a)(15)(P)(i) 
                        or 101(a)(15)(P)(iii),'' and inserting ``clause 
                        (i), (iii), or (iv) of section 
                        101(a)(15)(P),''; and
                            (ii) by striking ``of athletics or 
                        entertainment''.
                    (C) Expedited procedures.--Section 214(c)(6)(E)(i) 
                of the Immigration and Nationality Act (8 U.S.C. 
                1184(c)(6)(E)(i)) is amended by striking ``artists or 
                entertainers'' and inserting ``artists, entertainers, 
                or fashion models''.
    (b) Elimination of H-1B Classification for Fashion Models.--Section 
101(a)(15)(H)(i)(b) of the Immigration and Nationality Act (8 U.S.C. 
1101(a)(15)(H)(i)(b)) is amended--
            (1) by striking ``or as a fashion model''; and
            (2) by striking ``or, in the case of a fashion model, is of 
        distinguished merit and ability''.
    (c) Effective Date and Implementation.--
            (1) In general.--The amendments made by this section shall 
        take effect on the date of the enactment of this Act.
            (2) Regulations, guidelines, and precedents.--The 
        regulations, guidelines and precedents in effect on the date of 
        the enactment of this Act for the adjudication of petitions for 
        fashion models under section 101(a)(15)(H)(i)(b) of the 
        Immigration and Nationality Act (8 U.S.C. 
        1101(a)(15)(H)(i)(b)), shall be applied to petitions for 
        fashion models under section 101(a)(15)(P)(iv) of the 
        Immigration and Nationality Act (8 U.S.C. 1101(a)(15)(P)(iv)), 
        as added by this Act, except to the extent modified by the 
        Secretary of Homeland Security through final regulations (not 
        through interim regulations) promulgated in accordance with 
        subchapter II of chapter 5, and chapter 7, of title 5, United 
        States Code (commonly known as the ``Administrative Procedure 
        Act'').
            (3) Construction.--Nothing in this section shall be 
        construed as preventing an alien who is a fashion model from 
        obtaining nonimmigrant status under section 101(a)(15)(O)(i) of 
        the Immigration and Nationality Act (8 U.S.C. 
        1101(a)(15)(O)(i)) if such alien is otherwise qualified for 
        such status.
            (4) Treatment of pending petitions.--Petitions filed on 
        behalf of fashion models under section 101(a)(15)(H)(i)(b) of 
        the Immigration and Nationality Act (8 U.S.C. 
        1101(a)(15)(H)(i)(b)) that are pending on the date of the 
        enactment of this Act shall be treated as if they had been 
        filed under section 101(a)(15)(P)(iv) of the Immigration and 
        Nationality Act (8 U.S.C. 1101(a)(15)(P)(iv)), as added by this 
        Act.

Output: Amends the Immigration and Nationality Act to replace the current nonimmigrant (H-1B) visa category for fashion models with a new (P-4) visa category.

Defines such category as a fashion model who is of distinguished merit and ability and who is seeking to enter the United States temporarily to perform fashion modeling services that involve events or productions which have a distinguished reputation or that are performed for an organization or establishment that has a distinguished reputation for, or a record of, utilizing prominent modeling talent.

Provides that such entrants may not: (1) exceed 1,000 in any fiscal year, not including accompanying spouses or children; and (2) stay in the United States for more than 10 years (initial five-year period with one five-year extension).

Makes an employer petition for such alien models eligible for expedited consultation procedures.

States that applicable H-1B regulations, guidelines, and precedents in effect on the date of the enactment of this Act for the adjudication of fashion model petitions shall be applied to P-4 petitions, except to the extent modified by the Secretary of Homeland Security.


Input: Consider Input: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Stop Tampering of Prescription Pills 
Act of 2012''.

SEC. 2. TAMPER-RESISTANT TECHNOLOGY.

    (a) Definition.--Section 201 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 321) is amended by adding at the end the 
following:
    ``(ss) The term `tamper-resistant drug' means a drug that--
            ``(1) contains as an active moiety a controlled substance 
        that has been classified as opium, an opiate, or a derivative 
        thereof, as such terms are defined or used in section 102 of 
        the Controlled Substances Act;
            ``(2) has been formulated for oral administration; and
            ``(3)(A) exhibits physicochemical properties (demonstrated 
        by in vitro, in vivo, or other testing, or some combination 
        thereof, as determined appropriate by the Secretary) that make 
        product manipulation significantly more difficult or 
        ineffective in altering the characteristics of the drug for 
        purposes of misuse or abuse when compared to drugs without such 
        properties; or
            ``(B) contains one or more additional active or inactive 
        ingredients that are intended to deter abuse through potential 
        pharmacological effects, the effectiveness of which has been 
        demonstrated by at least one adequate and well-controlled 
        investigation.''.
    (b) Required Information in Application for Approval of Brand Name 
Drugs.--Section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355(b)) is amended by adding at the end the following:
            ``(7) Tamper-resistant drugs.--If an application submitted 
        under this subsection is potentially subject to refusal under 
        subsection (d)(7), the application shall include such 
        information as the Secretary determines necessary to 
        demonstrate that the application is not subject to such 
        refusal.''.
    (c) Approval of New Brand Name Drugs.--Section 505(d) of the 
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(d)) is amended--
            (1) by inserting ``(7)(A) such drug has been formulated for 
        oral administration; (B) such drug contains as an active moiety 
        a controlled substance that has been classified as opium, an 
        opiate, or a derivative thereof, as such terms are defined or 
        used in section 102 of the Controlled Substances Act; (C) such 
        drug is not a tamper-resistant drug; and (D) the Secretary has 
        previously approved pursuant to an application submitted under 
        subsection (b) or (j) a drug that (i) contains the same active 
        moiety; (ii) is a tamper-resistant drug, and (iii) has not been 
        discontinued from marketing; or'' after ``(6) the application 
        failed to contain the patent information prescribed by 
        subsection (b); or'';
            (2) by striking ``(7) based on fair'' and inserting ``(8) 
        based on fair'';
            (3) by striking ``clauses (1) through (6)'' and inserting 
        ``paragraphs (1) through (7)''; and
            (4) by inserting ``The Secretary may issue an order 
        approving an application, even if paragraph (7) applies, upon a 
        finding that paragraphs (1) through (6) and paragraph (8) do 
        not apply and that such approval is necessary either to prevent 
        or alleviate a drug shortage or to otherwise address a 
        significant unmet public health need.'' before ``As used in 
        this subsection and subsection (e)''.
    (d) Generic Drugs.--Section 505(j) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(j)) is amended--
            (1) in paragraph (2)--
                    (A) subparagraph (A)--
                            (i) in clause (vii), by striking ``and'' at 
                        the end;
                            (ii) in clause (viii), by striking the 
                        period at the end and inserting ``; and'';
                            (iii) by inserting after clause (viii) the 
                        following:
            ``(ix) if the listed drug is a tamper-resistant drug due to 
        its physicochemical properties, information from comparative in 
        vitro, in vivo, or other testing, or some combination thereof, 
        as appropriate based on the type of data submitted for the 
        listed drug, that demonstrates the new drug resists 
        manipulation or the effect of manipulation to a degree at least 
        comparable to the listed drug.''; and
                            (iv) in the continuation text at the end of 
                        the subparagraph, by striking ``clauses (i) 
                        through (viii)'' and inserting ``clauses (i) 
                        through (ix)'';
                    (B) in subparagraph (C)--
                            (i) in clause (i), by striking ``or'' at 
                        the end;
                            (ii) in clause (ii), by striking the period 
                        at the end and inserting ``; or''; and
                            (iii) by adding at the end the following:
            ``(iii) that the listed drug is a tamper-resistant drug and 
        one or more of the new drug's active moieties differ in any 
        material respect (in amount or otherwise) from those of the 
        listed drug.'';
            (2) in paragraph (5), by adding at the end the following:
    ``(G) If a drug has been approved pursuant to an application 
submitted under paragraph (2), and thereafter the listed drug referred 
to in the application becomes a tamper-resistant drug, the drug so 
approved shall not be considered to be bioequivalent to, or to have the 
same therapeutic effect as, the listed drug (as described in paragraph 
(2)(A)(iv)) unless and until the drug so approved has been found by the 
Secretary to meet the requirements of paragraph (2)(A)(ix).''; and
            (3) in paragraph (6)--
                    (A) by striking ``(6) If a drug'' and inserting 
                ``(6)(A) If a drug'';
                    (B) by striking ``(A) for the'' and inserting ``(i) 
                for the'';
                    (C) by striking ``(B) if the'' and inserting ``(ii) 
                if the''; and
                    (D) by adding at the end the following:
    ``(B) For purposes of this paragraph and paragraph (7)(C), a 
withdrawal or suspension of a drug formulated for oral administration 
shall be considered to have been for safety or effectiveness reasons 
if--
            ``(i) the approval of a listed drug, which is not a tamper-
        resistant drug, is withdrawn or suspended, or a listed drug, 
        which is not a tamper-resistant drug, is withdrawn from sale; 
        and
            ``(ii) the Secretary has previously approved pursuant to an 
        application under subsection (b) a drug that--
                    ``(I) is in the same dosage form;
                    ``(II) contains the same controlled substance as an 
                active moiety;
                    ``(III) is a tamper-resistant drug; and
                    ``(IV) has not been discontinued from marketing.''.
    (e) Withdrawal of Previously Approved Brand Name and Generic 
Drugs.--Section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355(e)) is amended--
            (1) by inserting ``or (6)(A) the drug contains as an active 
        moiety a controlled substance that has been classified as 
        opium, an opiate, or a derivative thereof, as such terms are 
        defined or used in section 102 of the Controlled Substances 
        Act; (B) the drug is formulated for oral administration; (C) 
        the drug is not a tamper-resistant drug; and (D) the Secretary 
        has previously approved pursuant to an application submitted 
        under subsection (b) or (j) a drug that contains the same 
        active moiety, is a tamper-resistant drug, and has not been 
        discontinued from marketing'' before ``: Provided,''; and
            (2) by adding at the end the following: ``The Secretary may 
        waive the application of paragraph (6) of the first sentence of 
        this subsection in the case of a drug intended for use in a 
        special needs population. In withdrawing (under paragraph (6) 
        of the first sentence of this subsection) the approval of an 
        application with respect to any drug, the Secretary shall, on a 
        case-by-case basis, delay the effective date of such withdrawal 
        for a period deemed sufficient by the Secretary to give the 
        sponsor an opportunity to obtain approval under this section 
        for a formulation of the drug meeting the criteria described in 
        paragraph (2) of the definition of a `tamper-resistant drug' in 
        section 201(ss).''.
    (f) Listed Drugs.--Section 505(j)(7) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 355(j)(7)) is amended by adding at the end the 
following:
    ``(D) Beginning 60 days after the date of the enactment of the Stop 
Tampering of Prescription Pills Act of 2012, the Secretary shall--
            ``(i) include in the list under subparagraph (A) a list of 
        each drug or category of drugs which the Secretary has found to 
        be tamper-resistant drugs; and
            ``(ii) update the list under subparagraph (A)--
                    ``(I) to remove from the list of tamper-resistant 
                drugs any drug the Secretary later determines is not a 
                tamper-resistant drug; and
                    ``(II) as required by subparagraph (C) to reflect 
                the application of paragraph (6)(B) to drugs that are 
                withdrawn or suspended.''.


Output: Stop Tampering of Prescription Pills Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to prescribe new drug application requirements for tamper-resistant drugs: (1) containing as an active moiety (the part of the drug that makes it work the way it does) a controlled substance classified as opium, an opiate, or a derivative; (2) formulated for oral administration; (3) exhibiting physicochemical properties making them significantly more difficult or ineffective in altering the drug's characteristics for purposes of misuse or abuse; and (4) containing one or more additional ingredients intended to deter abuse through potential pharmacological effects.

Requires the Secretary to refuse a new drug application for any new (brand name) drug containing opium, an opiate, or a derivative as an active moiety that is not tamper-resistant if a tamper-resistant drug containing the same active moiety has been approved and has not been discontinued from marketing. Authorizes the Secretary to approve an application failing to meet such requirements, however, if approval is necessary to prevent or alleviate a drug shortage or otherwise address a significant unmet public health need.

Requires an abbreviated new (generic) drug application for a tamper-resistant drug to include testing information demonstrating that the generic drug resists manipulation or the effect of manipulation to a degree at least comparable to the listed drug. Authorizes the Secretary to deny approval of a generic application if the listed drug is tamper-resistant and one or more of the generic drug's active moieties differ in any material respect from those of the listed drug.

Declares that an approved generic drug shall not be considered bioequivalent to, or as having the same therapeutic effect as, a listed drug if the listed drug becomes tamper-resistant unless and until the generic drug demonstrates that it resists manipulation or the effect of manipulation to a degree at least comparable to the listed drug.

Prescribes requirements governing when a drug which is not tamper-resistant may have its approval withdrawn or suspended.